Isotopic evaluation and therapy in patients with malignant endocrine disease

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 15, Issue 2, 2001, Pages 225-239

  Lewington, Valerie J ^a   Clarke, Susan E M ^b  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Radionuclide imaging; Radiopharmaceutical; Somatostatin receptor; Targeted radiotherapy; Tumour

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 5 HYDROXYINDOLEACETIC ACID; 5 HYDROXYTRYPTOPHAN; ANGIOPEPTIN; CARCINOEMBRYONIC ANTIGEN; CHOLECYSTOKININ B RECEPTOR; CHROMOGRANIN A; DEXAMETHASONE; FLUORODEOXYGLUCOSE F 18; GASTRIN; GASTRIN RECEPTOR; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; OCTREOTIDE; PANCREAS POLYPEPTIDE; PENTETREOTIDE IN 111; PERTECHNETIC ACID TC 99M; RADIOISOTOPE; SODIUM IODIDE I 131; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SUCCIMER TC 99M; TETROFOSMIN TC 99M; THALLIUM CHLORIDE TL 201; THYROTROPIN; THYROXINE; TUMOR MARKER; UNINDEXED DRUG; YTTRIUM 90;

ADRENAL CORTEX TUMOR; ADRENALECTOMY; BETA RADIATION; BONE MARROW SUPPRESSION; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SCINTISCANNING; CARCINOID; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; DRUG TOLERABILITY; ENDOCRINE DISEASE; FOLLOW UP; GAMMA IRRADIATION; GASTRINOMA; GLUCAGONOMA; HUMAN; INSULINOMA; LONG TERM CARE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NUCLEAR MEDICINE; PARATHYROID TUMOR; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TARGET ORGAN; THYROID CANCER; THYROIDECTOMY; WHOLE BODY SCINTISCANNING;

EID: 0034903870     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1053/beem.2001.0137     Document Type: Article

References (94)

1. Prognostic factors in thyroid carcinoma
2. Natural history, treatment, and course of papillary thyroid carcinoma
3. Treating differentiated thyroid carcinoma: Where do we draw the line?
4. The significance of I-131 scan dose in patients with thyroid cancer: Determination of ablation
5. Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients
6. Stunned thyroid after high-dose 1-131 imaging
7. Thyroglobulin assay in the follow-up of patients with differentiated thyroid carcinoma: Comparison of its value in patients with or without normal residual tissue
8. The treatment of thyroid carcinoma with radioactive iodine
9. Papillary and follicular thyroid cancer
10. 131I for thyroid ablation
11. 131I to ablate normal thyroid tissue in patients for whom thyroid cancer has been resected
12. Fractionated doses of radio-iodine for ablation of past surgical thyroid tissue remnants
13. Relationship between effective radiation dose and outcome of radioiodine therapy for thyroid cancer
14. Treatment of metastatic thyroid cancer
15. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer
16. Iodine 131 treatment of thyroid cancer: Absorbed dose calculated from post therapy scans
17. Therapie des Metastasierenden Schilddrüsenadenokarzinomas mit 131-Jod. Erfahrungen bei 103 Patienten aus dem Zeitraum 1963 bis 1977
18. The advantage of lithium in association with iodine 131 in the treatment of functioning metastases of thyroid cancer
19. Use of lithium as an adjunct to radioiodine therapy of thyroid carcinoma
20. The comparative value of serum thyroglobulin measurements and iodine-131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer
21. A comparison of recombinant thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer
22. I-131 therapy for elevated thyroglobulin levels
23. Distant metastases in papillary thyroid cancer: A review of 91 patients
24. Thallium-201, technetium-99m-tetrofosmin and iodine-131 in detecting differentiated thyroid carcinoma metastases
25. 201TI uptake, nuclear DNA content and clinical behavior in metastatic thyroid carcinoma
26. Evaluation of technetium-99m-MIBI scintigraphy in metastatic differentiated thyroid carcinoma
27. 131I ablative therapy
28. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma
29. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma
30. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: Contribution for patients with negative radioiodine scan
31. [18F]-2-Fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131) whole body scans and elevated serum thyroglobulin levels
32. 131I whole-body scan
33. Detection and localisation of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with Tc99m sestamibi (double phase study)
34. Location of parathyroid adenomas by thallium-201 and technetium-99m subtraction imaging
35. Diagnosis and management of asymptomatic primary hyperparathyroidism: Consensus development conference statement
36. Adrenal cortical and medullary imaging
37. Dexamethasone modified adrenal scintiscans in hyporeninemia aldosteronism (tumour b. hyperplasia): A comparison with adrenal venography and adrenal venous aldosterone
38. Scintigraphic localisation of phaeochromocytoma
39. Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine
40. Labetalol reduces I-131 mIBG uptake by phaeochromocytoma and normal tissues
41. Imaging of phaeochromocytoma and adrenal medulla with I-123 mIBG
42. The diagnosis of non-functional phaeochromocytoma: The role of mIBG imaging
43. Location of adrenal medullary phaeochromocytoma by I-123 metaiodobenzylguanidine SPECT
44. Metastatic pulmonary phaeochromocytomas: Positive I-123 mIBG SPECT with negative I-131 mIBG and equivocal I-123 mIBG planar imaging
45. Radio iodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumours
46. The spectrum of phaeochromocytoma in hypertensive patients with neurofibromatosis
47. Endocrine imaging: Parathyroid, adrenal cortex and medulla and other endocrine tumours. Part II
48. Malignant potential of phaeochromocytoma(p): Implications for follow up
49. Complimentary roles of CT scanning and I-131 mIBG scintigraphy in the diagnosis of phaeochromocytoma
50. Radiolabelled metaiodobenzylguanidine targeted radiotherapy for malignant phaeochromocytoma
51. Comparison of radiolabelled octreotide and metaiodobenzylguanidine (mIBG) scintigraphy in malignant phaeochromocytoma
52. Somatostatin receptor scintigraphy with In-III DTPA-D-Phe] and I-123 Tyr-3]-octreotide: The Rotterdam experience with more than 1000 patients
53. Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma
54. Mack Forster Award Lecture. Receptor nuclear medicine: Vasoactive peptide and somatostatin receptor scintigraphy for diagnosis and treatment of tumour patients
55. Comparison of (III) in labelled somatostatin analogues for tumours scintigraphy and radionuclide therapy
56. Phaeochromocytomas that do not accumulate metaiodobenzylguanidine: Localisation with PET and administration of FDG
57. Positron emission tomography (PET) with flurodeoxyglucose F 18 in the study of adrenal masses: Comparison of benign and malignant lesions
58. Malignant phaeochromocytoma of the anterior mediastinum: PET findings with F-18 FDG and Rb82
59. Treatment planning for mIBG radiotherapy of neural crest tumours using I-124 mIBG PET
60. PET scanning with hydroxyephedrine: An approach to the localisation of phaeochromocytoma
61. PET pharmacokinetics of 18F octreotide: A comparison with 67Ga-DFO and 86Y-DTPA octreotide
62. Malignant phaeochromocytoma: Effective treatment with a combination of cyclophosphamide, vincristine and dacarbazine
63. Chairman's report: The role of I-131 mIBG in the treatment of malignant phaeochromocytoma
64. MIBG therapy
65. Scintigraphic imaging of carcinoid tumours with I-131 mIBG
66. Somatostatin receptor scintigraphy of carcinoid tumours using the [In-IIII-DTPA-D-PheI]-octreotide
67. SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumours
68. Neuroendocrine tumour imaging: Can 18F fluorodeoxyglucose positron emission tomography detect tumours with poor prognosis and aggressive behaviour?
69. Positron emission tomography with 5-hydroxytryptophan in neuroendocrine tumours
70. Therapy of neuroendocrine tumours with radiolabelled somatostatin analogues
71. Clinical value of Y-90-DOTA-D-Phe-try-octreotide (Y-90 DOTATOC) of neuroendocrine tumour: First phase II study
72. Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy
73. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumours
74. Intraoperative use of gamma-detecting probes to localise neuroendocrine tumours
75. Cholecystokinin-B/gastrin receptor binding peptides: Preclinical development and evaluation of their diagnostic and therapeutic potential
76. 99mTc (V)DMSA in the diagnostic value of MTC
77. 99mTc-pentavalent-DMSA for imaging patients with medullary carcinoma of the thyroid
78. Registration of MR and SPECT images in medullary thyroid carcinoma
79. 186Re-V-DMSA: Dosimetry of a new radiopharmaceutical for therapy of medullary carcinoma of the thyroid
80. 99mTc MIBI imaging in the follow up of patients with MTC
81. 131 MIBG scintigraphy of neuroendocrine tumours other than phaeochromocytoma and neuroblastoma
82. Diagnostic and therapeutic potential of new radiopharmaceutical agents in medullary thyroid carcinoma
83. Contribution of different scintigraphic techniques to the management of MTC
84. Immunoscintigraphy in MTC using 1231 or 1111n labelled monoclonal anti CEA antibody fragment
85. Localisation of metastases from medullary thyroid carcinoma using different methods
86. Medullary thyroid carcinoma imaging in an animal model: Use of radiolabelled anti-calcitonin F(ab')2 and metaiodobenzyl guanidine
87. 111indium labeled DTPA dimer
88. 111In labeled bivalent hapten. A multicentre study of 42 patients with elevated thyrocalcitonin levels
89. Somatostatin receptor imaging in medullary thyroid carcinoma
90. Use of somatostatin analog SMS 201-995 in MTC